# 바이오스페이스 일일 뉴스 리포트 - 2025년 11월 12일


## 주요 헤드라인

1. **Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025 (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/amgen-merck-novo-more-take-cardiovascular-benefits-to-new-heights-at-aha-2025>

2. **Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025 (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/amgen-merck-novo-more-take-cardiovascular-benefits-to-new-heights-at-aha-2025>

3. **Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/neurocrines-depression-drug-delivers-surprise-phase-ii-miss>

4. **Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/neurocrines-depression-drug-delivers-surprise-phase-ii-miss>

5. **Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/cogent-hits-unprecedented-efficacy-in-rare-stomach-cancer-clearing-path-to-fda>

6. **Drugmakers Push FDA To Extend Support to Existing Facilities (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/drugmakers-push-fda-to-extend-support-to-existing-facilities>

7. **Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/kezar-loses-70-of-staff-after-fda-cancels-meeting-on-autoimmune-asset>


---
*2025년 11월 12일 바이오스페이스 뉴스 피드에서 생성된 리포트*